Alliance Pharma PLC has announced the issuance of options over 906,862 ordinary shares of 1 pence each in the Company to Nick Sedgwick, the Chief Executive Officer, as part of the Long-Term Incentive Plan 2019. These awards have been granted at nil-cost and are subject to continued employment and performance conditions based on EPS, TSR, and ROCE targets, becoming exercisable on 24 June 2027. The notification provides detailed information in accordance with the UK Market Abuse Regulation.

The transaction involved the grant of 906,862 options to acquire ordinary shares of 1 pence each at nil-cost, and it took place outside of a trading venue on 24 June 2024. The purpose of this grant is to align the interests of the directors with the long-term success of the company.

Alliance Pharma PLC is a growing consumer healthcare company with a focus on empowering people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company aims to achieve organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. Additionally, it may consider selective, complementary acquisitions to enhance its organic growth.

For further information, individuals can contact Alliance Pharma PLC through the provided contact details.

This news release provides insight into the company's approach to incentivizing and retaining key executives, as well as its strategic focus on sustainable growth and global brand expansion.